Across TCGA pan-cancer cohorts, TAS2R8 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of TAS2R8’s most consistent transcriptional readouts.
The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where TAS2R8 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TAS2R8 is over-expressed in tumor.
LIHC and KIRC are the cancer types where TAS2R8 tumor–normal differential expression is most reproducible.